NCT04914598 - A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions | Biotech Hunter

Enrollment

290

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

October 30, 2023

Conditions

Malignant Pleural Effusion

Interventions

DRUG

ENDOSTAR，cisplatin

After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment

DRUG

Placebo , cisplatin

Trial Locations (1)

Unknown

Xiaoying Wang, Shanghai